Randomized open-label study of second-generation antipsychotics for the treatment of schizophrenia: 104-week final results of the JUMPs study assessing treatment discontinuation, remission, and social functioning
Authors:
Open Access
- 5 September 2024
- journal article
- research article
- Published by Springer Nature in BMC Psychiatry
- Vol. 24 (1) , 1-14
Abstract
Background: We report the final results of treatment with aripiprazole, blonanserin, and paliperidone from the Japan Useful Medication Program for Schizophrenia (JUMPs), a 104-week naturalistic study. Methods: JUMPs was an open-label, three-arm, randomized, parallel-group, 104-week study. Patients aged ≥ 20 years with schizophrenia requiring antipsychotic treatment or a switch from previous therapy were enrolled. The primary endpoint was treatment discontinuation rate over 104 weeks. Secondary endpoints included remission rate, Personal and Social Performance (PSP), safety, Positive and Negative Syndrome Scale (PANSS), and quality of life (QOL; EuroQol-5 dimension). Results: In total, 251 patients received aripiprazole (n = 82), blonanserin (n = 85), or paliperidone (n = 84). Treatment discontinuation rates (aripiprazole, 80.5%; blonanserin, 81.2%; paliperidone, 71.4%) were not significantly different (p = 0.2385) among the treatment groups at 104 weeks; comparable outcomes were observed for endpoints, including remission (42.9%, 46.7%, and 45.8%), PANSS, and safety. In the overall cohort, while the improvement in the PSP total score at Week 104 was not significantly different from baseline, a significant improvement (p < 0.05) in QOL and total PANSS scores (including all subscales) was observed at Week 104 compared with baseline. Multivariable analysis identified a shorter disease duration and a higher chlorpromazine-equivalent antipsychotic dosage level (≥ 1000 mg) before switching to monotherapy as predictors of treatment discontinuation. Conclusions: The 104-week treatment outcomes were comparable between groups; the overall trend of improvement in remission rate, safety, and QOL suggests the importance of continued treatment. Clinical trial registration: UMIN-Clinical Trials Registry UMIN000007942 (public release date: 14/05/2012).Keywords
Funding Information
- Waksman Foundation of Japan, Inc.
This publication has 30 references indexed in Scilit:
- Predictors of clinical remission following a first episode of non-affective psychosis: Sociodemographics, premorbid and clinical variablesPsychiatry Research, 2013
- Symptomatic remission in schizophrenia patients: Relationship with social functioning, quality of life, and neurocognitive performanceSchizophrenia Research, 2011
- New advances in pharmacotherapy for early psychosisEarly Intervention in Psychiatry, 2009
- Efficacy and Tolerability of Olanzapine, Quetiapine, and Risperidone in the Treatment of Early Psychosis: A Randomized, Double-Blind 52-Week ComparisonAmerican Journal of Psychiatry, 2007
- Clinical trials: Bridging the gap between efficacy and effectivenessInternational Review of Psychiatry, 2007
- What does the PANSS mean?Schizophrenia Research, 2005
- Remission in Schizophrenia: Proposed Criteria and Rationale for ConsensusAmerican Journal of Psychiatry, 2005
- The InterSePT scale for suicidal thinking reliability and validitySchizophrenia Research, 2003
- Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning.2000
- Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of PsychosesArchives of General Psychiatry, 1988